Table 1.
Demographic and clinical characteristics of patients
| Characteristic | Total (n = 151) | Chemotherapy only (control) (n = 77) | Immunotherapy (n = 74) | P |
|---|---|---|---|---|
| Sex, male/female | 101/50 | 58/19 | 43/31 | 0.037 |
| Age (year), median ± SE | 57.0 ± 1.2 | 56 ± 1.5 | 58 ± 2.1 | 0.692 |
| ECOG performance status | ||||
| 0/1 | 136 | 69 | 67 | 0.915 |
| 2 | 15 | 8 | 7 | |
| Surgical procedure | ||||
| Partial gastrectomy | 82 | 39 | 40 | 0.745 |
| Total gastrectomy | 69 | 38 | 34 | |
| Location of tumor | ||||
| Upper | 39 | 18 | 21 | 0.772 |
| Middle | 41 | 22 | 19 | |
| Lower | 71 | 37 | 34 | |
| Pathological type of tumor | ||||
| Intestinal type | 98 | 51 | 47 | 0.598 |
| Diffuse | 42 | 22 | 20 | |
| Mixed type | 11 | 4 | 7 | |
| Histologic differentiation | ||||
| Well differentiated | 41 | 23 | 18 | 0.644 |
| Poorly differentiated | 78 | 37 | 41 | |
| Signet-ring cell | 32 | 17 | 15 | |
| UICC stage | ||||
| IIIA | 46 | 24 | 22 | 0.837 |
| IIIB | 72 | 35 | 37 | |
| VI | 33 | 18 | 15 | |
| Chemotherapy regimen | ||||
| Cisplatin | 28 | 18 | 10 | 0.101 |
| Oxaliplatin | 79 | 34 | 45 | |
| Docetaxel | 44 | 25 | 19 | |
SE indicates standard error; ECOG Eastern Cooperative Oncology Group, UICC International Union Against Cancer